Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 580,731,584
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • 60-Month Beta 0.41
  • Price/Sales 17.18
  • Price/Cash Flow 42.76
  • Price/Book 37.34
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 28.06% ( -1.60%)
  • Historical Volatility 36.03%
  • IV Percentile 48%
  • IV Rank 24.89%
  • IV High 44.88% on 08/03/23
  • IV Low 22.48% on 06/13/23
  • Put/Call Vol Ratio 0.62
  • Today's Volume 32,103
  • Volume Avg (30-Day) 38,497
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 269,559
  • Open Int (30-Day) 266,273

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.79
  • Number of Estimates 2
  • High Estimate 0.79
  • Low Estimate 0.78
  • Prior Year 0.63
  • Growth Rate Est. (year over year) +25.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.91 +7.69%
on 02/29/24
138.28 -7.40%
on 03/07/24
+5.82 (+4.76%)
since 02/27/24
3-Month
101.71 +25.90%
on 01/02/24
138.28 -7.40%
on 03/07/24
+24.37 (+23.51%)
since 12/27/23
52-Week
75.56 +69.47%
on 07/11/23
138.28 -7.40%
on 03/07/24
+50.70 (+65.55%)
since 03/27/23

Most Recent Stories

More News
Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?

Their joint project is cutting-edge, but it won't pay off immediately.

NVO : 128.05 (-1.05%)
NVDA : 902.50 (-2.50%)
Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

NVO : 128.05 (-1.05%)
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

All three of these high-flying stocks could have more room to run.

CTLT : 56.48 (+0.39%)
NVO : 128.05 (-1.05%)
LLY : 778.18 (+0.42%)
VKTX : 83.34 (+3.11%)
Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market

Artificial intelligence (AI) could play a big role in medical breakthroughs.

NVO : 128.05 (-1.05%)
Novo Nordisk Buys Cardior Pharma For $1.1 Billion

Danish pharmaceutical giant Novo Nordisk (NVO) is buying privately held Cardior Pharmaceuticals for ...

NVO : 128.05 (-1.05%)
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition

Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.

NVO : 128.05 (-1.05%)
LLY : 778.18 (+0.42%)
VKTX : 83.34 (+3.11%)
PFE : 27.78 (+0.69%)
Is Viking Therapeutics Stock a Millionaire Maker?

Viking Therapeutics has become one of the hottest healthcare stocks of 2024.

NVO : 128.05 (-1.05%)
VKTX : 83.34 (+3.11%)
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?

The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.

LLY : 778.18 (+0.42%)
VKTX : 83.34 (+3.11%)
NVO : 128.05 (-1.05%)
Did Eli Lilly Just One-Up Novo Nordisk?

Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.

AMZN : 179.83 (+0.86%)
NVO : 128.05 (-1.05%)
LLY : 778.18 (+0.42%)
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy

Has Novo Nordisk's already red-hot stock become an even better buy?

NVO : 128.05 (-1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 130.01
2nd Resistance Point 129.32
1st Resistance Point 128.68
Last Price 128.05
1st Support Level 127.35
2nd Support Level 126.66
3rd Support Level 126.02

See More

52-Week High 138.28
Last Price 128.05
Fibonacci 61.8% 114.32
Fibonacci 50% 106.92
Fibonacci 38.2% 99.52
52-Week Low 75.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar